Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Genfit   /   Koers Genfit 2017

Aandeel Genfit PSE:GNFT.FR, FR0004163111

Laatste koers (eur) Verschil Volume
3,940   -0,040   (-1,01%) Dagrange 3,905 - 4,005 169.890   Gem. (3M) 312,7K

Koers Genfit 2017

Volgen
259 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 13 »» | Laatste | Omlaag ↓
  7. [verwijderd] 23 maart 2017 13:25
    03-23-2017 06:20 AM CET - Health & Medicine

    Elafibranor Could be Just the Thing to Boost the Global Non-alcoholic Steatohepatitis Therapeutics Market
    There are a few key causes of a fatty liver, one of which is non-alcoholic fatty liver disease. It occurs when excessive alcohol consumption causes large deposits of fat in the liver. It is one of the most commonly linked diseases to alcoholism and also one of the most commonly found liver disorders in developed economies. Non-alcoholic fatty liver disease (NAFLD) is caused by reasons linked to metabolic issues and insulin resistance. Obesity is another factor that can significantly increase the chances of contracting NAFLD.

    According to the National Health and Nutrition Examination Survey, the rate of NAFLD in the U.S. within 2011 and 2012 was nearly 30%. In cases where NAFLD was not detected in time and reached higher levels of complications, non-alcoholic steatohepatitis (NASH) can occur. It is the most extreme form of non-alcoholic fatty liver disease and is a direct causative factor for liver cirrhosis. NAFLD by itself can be treated successfully if detected in time. NASH, on the other hand, needs special care.

    The global non-alcoholic steatohepatitis therapeutics market is expected to reach US$20.2 bn by the end of 2025. It is expanding at a CAGR of 10.70% between 2015 and 2025. The key players in this market that are expected to play a major role in the market’s immediate future include Tobira Therapeutics, Inc., Conatus Pharmaceuticals, Immuron Ltd., Zydus Cadila, Gilead Sciences, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., and Astazeneca Plc.

    Elafibranor Propels Global NASH Market

    The major segments of the market by drug type include Saroglitazar, Aramchol, Elafibranor, Obeticholic acid, and potential drug candidates in phase III. Elafibranor is expected to lead the market in the near future by being the largest and fastest growing segment of the global non-alcoholic steatohepatitis therapeutics market. Elafibranor is currently the most advanced and most effective drug in this market and is expected to exhibit the highest CAGR of all the various drug types.

    There are no treatments that are specifically used for non-alcoholic steatohepatitis. Apart from the various drugs used for the treatment of fatty liver, doctors often suggest the patient to start losing weight if they are overweight. Other suggestions given include completely avoiding alcohol, consuming a balanced diet, and increasing physical activity.

    NASH and NAFLD Linked to Obesity

    Medical records are pointing to an increasing prevalence of NAFLD and NASH across the world. However, these issues are more common in developed economies such as North America. This is due to the larger percentage of the obese population in the total population in developed regions than others. The global non-alcoholic steatohepatitis therapeutics market is, therefore, developing at a higher rate in countries such as the U.S., owing to the higher demand for NASH and NAFLD treatment options.

    The healthcare industry in these regions is taking fatty liver complications a lot more seriously. In the recent past, the number of obese adults and children in the U.S. have doubled and tripled, respectively. This is a major issue, as obese patients who suffer from NFALD or NASH are also likely to suffer from high blood cholesterol and diabetes.

    Apart from obesity, patients of glucose intolerance and dyslipidemia are also prone to suffer from NFALD and NASH. There is no clear link that points to the reason NFALD occurs, but it is currently suggested that insulin resistance has a major role to play in it. In spite of the severity of the disease, patients are largely asymptomatic until complications arise. Therefore, the best preventive measure against NFALD and NASH is to lead a healthy life and moderate alcohol consumption.

    About Us

    Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

    Contact Us

    Transparency Market Research
    State Tower,
    90 State Street, Suite 700
    Albany, NY 12207
    United States
    Tel: +1-518-618-1030
    USA - Canada Toll Free: 866-552-3453
    Email: sales@transparencymarketresearch.com
    Website: www.transparencymarketresearch.com

    This release was published on openPR.
    www.openpr.com/news/478663/Elafibrano...

  8. forum rang 10 DeZwarteRidder 23 maart 2017 14:15
    quote:

    Investor68 schreef op 23 maart 2017 13:25:

    03-23-2017 06:20 AM CET - Health & Medicine

    Elafibranor Could be Just the Thing to Boost the Global Non-alcoholic Steatohepatitis Therapeutics Market
    There are a few key causes of a fatty liver, one of which is non-alcoholic fatty liver disease. It occurs when excessive alcohol consumption causes large deposits of fat in the liver. It is one of the most commonly linked diseases to alcoholism and also one of the most commonly found liver disorders in developed economies. Non-alcoholic fatty liver disease (NAFLD) is caused by reasons linked to metabolic issues and insulin resistance. Obesity is another factor that can significantly increase the chances of contracting NAFLD.

    About Us

    Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

    Contact Us

    Transparency Market Research
    State Tower,
    90 State Street, Suite 700
    Albany, NY 12207
    United States
    Tel: +1-518-618-1030
    USA - Canada Toll Free: 866-552-3453
    Email: sales@transparencymarketresearch.com
    Website: www.transparencymarketresearch.com

    This release was published on openPR.
    www.openpr.com/news/478663/Elafibrano...
    Wat een boelshit-verhaal; het grenst aan oplichting...!!
  11. [verwijderd] 24 maart 2017 17:52
    Na 6 dagen winstneming / daling weer een redelijke stijging. Erg benieuwd (Ja Ridder jij weet zeker van niet) of er toch nog wat gebeuren de aankomende weken / maanden. Met wat ik lees (berichten van zwartkijkridder daar gelaten) heeft de markt er wel vertrouwen in, ook de bankman van Theodoor Gilissen.
  16. me_n 27 maart 2017 10:37
    quote:

    de speurneus schreef op 27 maart 2017 10:07:

    Dat denk ik ook 30€ bodem voorlopig.
    Maar duurt wel erg lang. Ketst het af dan zou de koers flink terug kunnen vallen.
    Zie september vorig jaar.
    Ben ik met je eens, maar geduld is een schone zaak.
    De volumes zijn vele malen groter dan september vorig jaar.
    Kan ook gewoon zijn dat de fase 3 resultaten die in juni bekend worden heel goed zijn. Gelukkig lijkt deze dag niet op die van 2 jaar geleden ;)
  17. forum rang 10 DeZwarteRidder 27 maart 2017 10:49
    quote:

    me_n schreef op 27 maart 2017 10:37:

    [...]Ben ik met je eens, maar geduld is een schone zaak.
    De volumes zijn vele malen groter dan september vorig jaar.
    Kan ook gewoon zijn dat de fase 3 resultaten die in juni bekend worden heel goed zijn. Gelukkig lijkt deze dag niet op die van 2 jaar geleden ;)
    Dus jij denkt dat criminelen misbruik maken van voorkennis en dat daarom de koers omhoog gaat...???
259 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 13 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee